A Novel High-throughput Droplet Digital PCR-based Indel Quantification Method for the Detection of Circulating Donor-derived Cell-free DNA After Kidney Transplantation
- 10 March 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9) , 1777-1786
Abstract
Background.: Donor-derived cell-free DNA (ddcfDNA) is a promising minimally invasive biomarker for acute rejection (AR) in kidney transplant recipients. To assess the diagnostic value of ddcfDNA as a marker for AR, ddcfDNA was quantified at multiple time points after kidney transplantation with a novel high-throughput droplet digital PCR indel method that allowed for the absolute quantification of ddcfDNA. Methods.: In this study, ddcfDNA in plasma samples from 223 consecutive kidney transplant recipients was analyzed pretransplantation; at 3, 7, and 180 d after transplantation; and at time of for-cause biopsies obtained within the first 180 d after transplantation. Results.: Median (interquartile range) ddcfDNA concentration was significantly higher on day 3 (58.3 [17.7-258.3] copies/mL) and day 7 (25.0 [10.4-70.8] copies/mL) than on day 180 after transplantation (4.2 [0.0-8.3] copies/mL; P < 0.001 and P < 0.001, respectively). At time of biopsy-proven AR (BPAR), between day 11 and day 180 after transplantation, ddcfDNA concentration was significantly higher (50.0 [25.0-108.3] copies/mL) than those when biopsies showed non-AR (0.0 [0.0-15.6] copies/mL; P < 0.05). ddcfDNA concentration within the first 10 d after transplantation showed no significant difference between recipients with BPAR and those with non-AR in their biopsy or between recipients with BPAR and ddcfDNA measured at day 3 and day 7. Conclusions.: Unfortunately, ddcfDNA concentration is not a good biomarker to detect AR within the first 10 d after transplantation; however, BPAR occurring after 10 d after transplantation can be detected in kidney transplant recipients by ddcfDNA using a novel and unique high-throughput droplet digital PCR indel method.Keywords
This publication has 26 references indexed in Scilit:
- Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipientsAmerican Journal of Transplantation, 2019
- Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic ReviewTransplantation, 2019
- Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCRJournal of Clinical Medicine, 2018
- Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assayPLOS ONE, 2018
- Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunctionAmerican Journal of Transplantation, 2018
- Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literatureHeliyon, 2018
- A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney TransplantationTransplantation, 2017
- Cell-Free DNA and Active Rejection in Kidney AllograftsJournal of the American Society of Nephrology, 2017
- Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant RejectionScience Translational Medicine, 2014
- A Rapid Noninvasive Assay for the Detection of Renal Transplant InjuryTransplantation, 2013